Table 2.
Case summary of MM-associated crystalline LCCN in which dialysis independence was achieved
| Case | Age, Gender |
sCr (mg/dl) |
UPCR | Light chain isotype |
Anti-myeloma therapy |
The time from symptom onset to anti-myeloma therapy initiation |
The duration of dialysis |
Hematological outcome |
|---|---|---|---|---|---|---|---|---|
|
Haider M [9] |
57, Male |
7.39 | 1.2 | λ | BD | 2 weeks | 4 weeks |
being evaluated for ASCT |
|
Lin ZS [3] |
59.5 [41, 73], N/A |
N/A | N/A | N/A | VAD | N/A | N/A |
CR at 3 months; clinical relapse and death |
|
Lin ZS [3] |
59.5 [41, 73], N/A |
N/A | N/A | N/A |
bortezomib- based |
N/A | N/A | PR at 13 months |
|
Matsumura M [4] |
73, Female |
5.59 | 9.1 | λ |
bortezomib, dexamethasone, lenalidomide, and pomalidomide |
N/A | 2 weeks | Died at 6 months |
| Chou A [7] | 74, Female | 8.62 | 0.55 g (proteinuria per day) | κ | CyBorD | 3 weeks | 2 months with 5 sessions of plasmapheresis | PR |
| Our case |
79, Male |
7.92 | 17.04 | λ | BD | 5 days | 3 weeks | PR at 1 month |
N/A not available, sCr serum creatinine, UPCR urine protein creatinine ratio, VAD vinorelbine, pirarubicin, and dexamethasone, CyBorD cyclophosphamide, bortezomib, and dexamethasone, BD bortezomib and dexamethasone, ASCT autologous stem cell transplant, CR complete remission ,PR, partial remission